NCT01166061View on ClinicalTrials.gov

Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Allergy
Interventions
BIOLOGICAL

Placebo

Solution resembling active solution but without peptides

BIOLOGICAL

ToleroMune Grass

1 x4 administrations 4 weeks apart

Trial Locations (1)

G1V 4M6

Centre de Recherche Appliqué en Allergie de Québec, Québec

Sponsors

Collaborators (1)

Adiga Life Sciences, Inc.
All Listed Sponsors
collaborator

Adiga Life Sciences, Inc.

INDUSTRY

lead

Circassia Limited

INDUSTRY

NCT01166061 - Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis | Biotech Hunter | Biotech Hunter